Medicines sues generic drugmakers over Angiomax patent
The Medicines Company has filed lawsuits against Teva Parenteral Medicines, Pliva Hrvatska and APP Pharmaceuticals over Angiomax (bivalirudin) patent infringement.

The Parsippany, N.J.-based company filed the lawsuit with U.S. District Court for the District of Delaware, alleging patent infringement based on abbreviated new drug applications seeking FDA approval to market and sell generic versions of Angiomax product prior to expiration of U.S. Patent No. 7,582,727 (the '727 patent).

Each lawsuit alleges infringement of the '727 patent, which was issued to Medicines on Sept. 1, and scheduled to expire in March of 2010. The company could have obtained a four-year extension had they not missed the deadline to file for extended patent exclusivity by merely a day.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup